The Delhi High Court has restrained Dr. Reddy’s and OneSource from selling semaglutide domestically—following Novo Nordisk’s lawsuit over alleged patent infringement tied to its blockbuster obesity drug Wegovy.
💡 But here’s the kicker: Semaglutide isn’t new.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
